These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
341 related articles for article (PubMed ID: 30249019)
1. The Role of Stroma in Cholangiocarcinoma: The Intriguing Interplay between Fibroblastic Component, Immune Cell Subsets and Tumor Epithelium. Gentilini A; Pastore M; Marra F; Raggi C Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30249019 [TBL] [Abstract][Full Text] [Related]
2. The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine. Rimassa L; Personeni N; Aghemo A; Lleo A J Autoimmun; 2019 Jun; 100():17-26. PubMed ID: 30862450 [TBL] [Abstract][Full Text] [Related]
3. The tumour microenvironment and immune milieu of cholangiocarcinoma. Fabris L; Perugorria MJ; Mertens J; Björkström NK; Cramer T; Lleo A; Solinas A; Sänger H; Lukacs-Kornek V; Moncsek A; Siebenhüner A; Strazzabosco M Liver Int; 2019 May; 39 Suppl 1(Suppl 1):63-78. PubMed ID: 30907492 [TBL] [Abstract][Full Text] [Related]
4. The role of tumour microenvironment: a new vision for cholangiocarcinoma. Chen Z; Guo P; Xie X; Yu H; Wang Y; Chen G J Cell Mol Med; 2019 Jan; 23(1):59-69. PubMed ID: 30394682 [TBL] [Abstract][Full Text] [Related]
5. Desmoplastic Tumor Microenvironment and Immunotherapy in Cholangiocarcinoma. Høgdall D; Lewinska M; Andersen JB Trends Cancer; 2018 Mar; 4(3):239-255. PubMed ID: 29506673 [TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of Cholangiocarcinoma Immune Biology. Vita F; Olaizola I; Amato F; Rae C; Marco S; Banales JM; Braconi C Cells; 2023 Mar; 12(6):. PubMed ID: 36980187 [TBL] [Abstract][Full Text] [Related]
8. Isolation and characterization of biliary epithelial and stromal cells from resected human cholangiocarcinoma: a novel in vitro model to study tumor-stroma interactions. Massani M; Stecca T; Fabris L; Caratozzolo E; Ruffolo C; Furlanetto A; Morton S; Cadamuro M; Strazzabosco M; Bassi N Oncol Rep; 2013 Sep; 30(3):1143-8. PubMed ID: 23807641 [TBL] [Abstract][Full Text] [Related]
10. Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review). Yang S; Zou R; Dai Y; Hu Y; Li F; Hu H Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37888583 [TBL] [Abstract][Full Text] [Related]
11. The Tumor Immune Microenvironment plays a Key Role in Driving the Progression of Cholangiocarcinoma. Zhang Y; Yan HJ; Wu J Curr Cancer Drug Targets; 2024; 24(7):681-700. PubMed ID: 38213139 [TBL] [Abstract][Full Text] [Related]
17. The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma. Cadamuro M; Stecca T; Brivio S; Mariotti V; Fiorotto R; Spirli C; Strazzabosco M; Fabris L Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1435-1443. PubMed ID: 28757170 [TBL] [Abstract][Full Text] [Related]
18. Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy. Louis C; Edeline J; Coulouarn C Expert Opin Ther Targets; 2021 Feb; 25(2):153-162. PubMed ID: 33502260 [No Abstract] [Full Text] [Related]
19. Tumor-associated macrophages: orchestrators of cholangiocarcinoma progression. Chen F; Sheng J; Li X; Gao Z; Hu L; Chen M; Fei J; Song Z Front Immunol; 2024; 15():1451474. PubMed ID: 39290697 [TBL] [Abstract][Full Text] [Related]
20. Heterogeneity, crosstalk, and targeting of cancer-associated fibroblasts in cholangiocarcinoma. Cantallops Vilà P; Ravichandra A; Agirre Lizaso A; Perugorria MJ; Affò S Hepatology; 2024 Apr; 79(4):941-958. PubMed ID: 37018128 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]